Active Filters
- Press ReleaseClear filter
![S1512 Cohort B results at AACR 2023](/sites/default/files/styles/news_recent/public/news/2023-04/press-card-S1512-Kendra-AACR-725x415.png?itok=oSZ1xMr4)
Apr 16, 2023
SWOG S1512 trial sees high response rate to pembrolizumab in patients with unresectable desmoplastic melanoma
![S2302 Pragmatica-Lung trial](/sites/default/files/styles/news_recent/public/news/2023-04/Pragmatica-Lung.FINAL_.20230412-725x415.png?itok=rdrOISYI)
Apr 12, 2023
SWOG S2302 Pragmatica-Lung study opens to enrollment, a model for easier, more representative clinical trials
![S1416 results in Lancet Oncology](/sites/default/files/styles/news_recent/public/news/2023-01/S1416-Sharma-LO-headline-2.png?itok=AScGgltl)
Jan 30, 2023
S1416 trial results show PARP inhibitor benefit in "BRCA-like" triple-negative breast cancer
![S1815 results at ASCO GI](/sites/default/files/styles/news_recent/public/news/2023-01/S1815-press-release-card.png?itok=v5JaE_7G)
Jan 20, 2023
Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some
![journal article title page](/sites/default/files/styles/news_recent/public/news/2022-12/NCTN-impact-cost-graphic-4.jpg?itok=jB3LfJuN)
Dec 19, 2022
Four decades of NCI-funded NCTN trials gave U.S. patients 14.2 million life-years for a federal investment of $326 per life-year gained
![S1404 QoL results](/sites/default/files/styles/news_recent/public/news/2022-11/press-release-card-S1404-QoL.png?itok=8Gu3L8Jc)
Nov 23, 2022
Patients with high-risk melanoma had better quality of life on pembrolizumab than on standard immunotherapy regimens
![SWOG Results at SABCS 2022](/sites/default/files/styles/news_recent/public/news/2022-11/press-release-card-SABCS22_1.png?itok=c8DF3-LO)
Nov 21, 2022
SWOG researchers will present 10 abstracts at SABCS 2022. Here are highlights.
![Stratification factors can reduce statistical power](/sites/default/files/styles/news_recent/public/news/2022-11/press-release-card-ASH22-Moseley.png?itok=iF_jL3-e)
Nov 3, 2022
Adding stratification factors can reduce a small trial’s statistical power
![S/N1806 toxicity data reveal no safety concerns](/sites/default/files/styles/news_recent/public/news/2022-10/press-release-card-Singh-ASTRO.png?itok=_fDc9nIH)
Oct 25, 2022